FDC Ltd. (FDC) AI Stock Analysis

• Market Cap: ₹55.18B
• Dividend Yield: 1.22%
• Average Volume (3M): 16.03K
• Price to Earnings (P/E): 60.8
• Beta (1Y): 0.82
• Revenue Growth: 0.25%
• EPS Growth: -28.79%
• Country: IN
• Employees: 6,659
• Sector: Services
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.74
• Shares Outstanding: 162,810,090
• 10 Day Avg. Volume: 4,978
• 30 Day Avg. Volume: 16,030
• PEG Ratio: -2.10
• Price to Book (P/B): 2.86
• Price to Sales (P/S): 3.10
• P/FCF Ratio: 24.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: ₹353.00 ▼(-13.92% Downside)
• Action: Reiterated Date: 11/11/25
• Date: Action: Reiterated 11/11/25

FDC Ltd.'s overall stock score is primarily influenced by its solid financial performance, which is offset by bearish technical indicators and a high valuation. The company's strong balance sheet and operational efficiency are positive factors, but the stock's current technical weakness and relatively high P/E ratio present challenges.

Positive Factors

Strong Balance Sheet

Conservative leverage and a high equity ratio provide durable financial flexibility: they reduce refinancing risk, preserve investment capacity for R&D or capacity expansion, and support credit access through cycles, bolstering resilience over the next several quarters.

Consistent Revenue and Stable Margins

Sustained top-line growth combined with stable gross and EBITDA margins indicates durable operational efficiency and pricing power. This mix supports long-term cash generation, ability to reinvest in growth initiatives, and steadier earnings through industry cycles.

Solid Cash Generation

Robust operating cash flow and rising free cash flow create a foundation for capital allocation flexibility—funding capex, dividends, or deleveraging—improving financial stability and enabling strategic moves without heavy external financing.

Negative Factors

EPS Decline

A more than 20% decline in EPS signals meaningful pressure on reported earnings that may stem from higher costs, pricing dynamics, or non-recurring items. Persistent EPS weakness can erode retained earnings and constrain internal funding for growth or shareholder returns.

Net Profit Margin Pressure

Even modest compression in net margins reduces cash available after operations and weakens long-term profitability. If structural, this can limit reinvestment, reduce resilience to cost inflation, and lower returns on equity over multiple quarters.

Imperfect Free Cash Flow Conversion

If accounting profits do not reliably convert into free cash, the company faces constraints funding capex, dividends, or M&A from internal sources. This conversion gap can persistently limit financial flexibility despite healthy reported earnings.

FDC Ltd. Business Overview & Revenue Model

Company Description

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl-LBW, Simyl-MCT, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. FDC Limited was founded in 1936 and is headquartered in Mumbai, India.

How the Company Makes Money

null

FDC Ltd. Financial Statement Overview

Summary

FDC Ltd. exhibits solid financial health with consistent revenue growth and strong balance sheet stability. While profitability metrics show some pressure, the company's operational efficiency and cash flow generation remain commendable. The low leverage and high equity ratio provide a cushion against potential risks.

Income Statement

FDC Ltd. has shown consistent revenue growth over the years, with a notable increase of 8.9% from 2024 to 2025. The gross profit margin has remained strong, reflecting efficient cost management. However, the net profit margin has slightly decreased, indicating some pressure on profitability. The EBIT and EBITDA margins are stable, showcasing operational efficiency.

Balance Sheet

The company's balance sheet is robust, with a low debt-to-equity ratio, indicating conservative leverage. The equity ratio is high, reflecting strong financial stability. Return on equity has decreased slightly, but remains healthy, suggesting effective use of shareholders' funds.

Cash Flow

FDC Ltd. has demonstrated strong free cash flow growth, with a significant increase from 2024 to 2025. The operating cash flow to net income ratio is favorable, indicating good cash generation relative to earnings. However, the free cash flow to net income ratio suggests room for improvement in converting profits into free cash flow.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	20.77B	21.08B	19.35B	17.84B	15.26B	13.27B
Gross Profit	12.64B	8.36B	6.51B	11.28B	9.78B	9.00B
EBITDA	3.66B	4.15B	4.40B	3.01B	3.30B	4.29B
Net Income	2.25B	2.67B	3.05B	1.94B	2.16B	3.01B
Balance Sheet
Total Assets	28.86B	27.14B	24.68B	23.43B	22.70B	19.56B
Cash, Cash Equivalents and Short-Term Investments	4.52B	5.37B	4.75B	4.84B	5.39B	5.57B
Total Debt	207.12M	211.68M	205.19M	283.20M	322.04M	146.56M
Total Liabilities	4.54B	4.33B	3.71B	3.62B	3.14B	2.22B
Stockholders Equity	24.31B	22.81B	20.97B	19.82B	19.57B	17.34B
Cash Flow
Free Cash Flow	-833.81M	2.67B	1.27B	418.21M	291.08M	1.45B
Operating Cash Flow	-19.40M	3.64B	2.21B	1.55B	1.62B	2.07B
Investing Cash Flow	-68.14M	-2.47B	-170.83M	111.35M	-1.45B	-771.54M
Financing Cash Flow	-70.98M	-913.47M	-2.02B	-1.80B	-98.37M	-1.29B

FDC Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 410.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FDC, the sentiment is Negative. The current price of 410.1 is above the 20-day moving average (MA) of 362.19, above the 50-day MA of 372.96, and below the 200-day MA of 428.66, indicating a bearish trend. The MACD of -9.32 indicates Positive momentum. The RSI at 33.30 is Neutral, neither overbought nor oversold. The STOCH value of 6.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:FDC.

FDC Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GPPL	75 Outperform	₹72.23B	20.41	―	4.98%	7.10%	29.89%
TCI	70 Outperform	₹72.41B	18.01	―	0.94%	9.97%	16.28%
IONEXCHANG	60 Neutral	₹50.17B	55.57	―	0.40%	11.56%	-2.78%
FDC	58 Neutral	₹55.18B	60.85	―	1.22%	0.25%	-28.79%
THOMASCOOK	58 Neutral	₹46.43B	41.31	―	0.32%	11.02%	-9.59%
PNCINFRA	57 Neutral	₹47.82B	21.04	―	0.23%	-30.54%	-35.13%
Sector *	55 Neutral	$13.29B	17.42	10.03%	0.93%	7.13%	-12.93%

FDC Ltd. Corporate Events

FDC Gets USFDA ANDA Nod for Fluconazole Tablets

FDC Ltd. has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application covering Fluconazole Tablets USP in strengths of 50 mg, 100 mg, 150 mg and 200 mg. The clearance enables FDC to market a generic version of the antifungal medicine in the United States, strengthening its presence in the key U.S. generics market and potentially expanding its revenue opportunities in the anti-infective segment.